At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRI GRI BIO INC
Trading 09-02 11:40:26 EDT
1.93
+0.02
+0.79%
High1.95
Low1.87
Vol25.43K
Open1.92
D1 Closing1.91
Amplitude4.18%
Mkt Cap4.21M
Tradable Cap4.21M
Total Shares2.19M
T/O48.55K
T/O Rate1.16%
Tradable Shares2.18M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Welltower, Other Senior Housing REITs to See More Upside as Occupancy Supports 2027 Growth, Morgan Stanley Says
Landmark Deal Marks New Milestone: ICBC Credit Suisse's Multi-Tier REIT Framework Reaches Another Key Achievement with First Inter-Institutional Product from a Banking-Affiliated Fund Subsidiary
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.